Gulf Coast fever (coccidioidomycosis) - Causes, Treatment & When to See a Doctor

```html

What is Gulf Coast fever (coccidioidomycosis)?

Gulf Coast fever, more formally known as coccidioidomycosis, is an infection caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. These organisms live in the soil of dry, arid regions of the southwestern United States, northern Mexico, parts of Central and South America, and some areas of the Middle East. When the soil is disturbed—by construction, wind, farming, or even a dust‑storm—tiny fungal spores (arthroconidia) become airborne and can be inhaled into the lungs.

Most people who inhale the spores develop either no symptoms or a mild, flu‑like illness that resolves on its own. However, a subset of individuals—particularly those with weakened immune systems, pregnancy, or certain underlying lung diseases—can develop more severe disease that spreads beyond the lungs to skin, bones, joints, or the central nervous system. Because the infection is endemic to specific geographic areas, clinicians often refer to it as “Valley fever” in California and “Gulf Coast fever” in the Gulf‑coast states, but both terms describe the same disease.

Common Causes

While the primary cause is exposure to Coccidioides spores, several conditions or situations increase the likelihood of contracting the infection or worsen its course:

• Soil disruption in endemic areas – construction, farming, digging, or off‑road vehicle use.
• Dust storms (haboob) or windy weather – can aerosolize large numbers of spores.
• Travel to endemic regions – even brief stays in deserts of Arizona, California, Texas, or the Gulf Coast can expose a person to spores.
• Immunosuppression – HIV/AIDS, organ transplantation, chemotherapy, or long‑term steroids.
• Pregnancy – especially in the third trimester; hormonal changes affect immunity.
• Chronic lung disease – COPD, asthma, or prior tuberculosis increase susceptibility.
• Diabetes mellitus – alters immune response and can lead to more severe disease.
• Age extremes – children under 5 and adults over 60 have higher risk of severe infection.
• Genetic factors – certain HLA types (e.g., HLA‑DRB1*1301) have been linked to more severe disease.
• Occupational exposure – military personnel, archaeologists, and outdoor laborers working in endemic zones.

Associated Symptoms

Symptoms can be divided into three broad categories: pulmonary (most common), disseminated, and complications.

Pulmonary (lung) manifestations

• Fever, chills, and night sweats
• Dry, non‑productive cough or, less commonly, a productive cough
• Chest pain that worsens with deep breathing
• Shortness of breath or wheezing
• Fatigue and generalized malaise
• Headache
• Muscle aches (myalgia) and joint pain (arthralgia)
• Rash – usually small red or purple spots (petechiae) that may appear on the trunk or limbs

Disseminated disease (spread beyond the lungs)

• Skin lesions – tender nodules that may ulcerate or form “pseudovesicles”
• Bone pain, especially in the ribs, spine, or long bones; may be accompanied by swelling
• Joint swelling and pain (arthritis)
• Granulomatous meningitis – headache, stiff neck, fever, confusion, or seizures (rare but serious)
• Enlarged lymph nodes (lymphadenopathy)

Complications

• Persistent cough lasting >3 months (post‑infectious fibrosis)
• Chronic pulmonary cavitation, which can become colonized with bacteria
• Secondary bacterial pneumonia
• Severe sepsis in immunocompromised patients

When to See a Doctor

Because early treatment can prevent severe complications, seek medical care if you experience:

• Fever ≥ 101 °F (38.3 °C) that lasts more than 48 hours after returning from an endemic area.
• Persistent cough, chest pain, or shortness of breath that does not improve within a week.
• New‑onset rash, especially if it is painful, nodular, or ulcerates.
• Unexplained joint or bone pain, particularly if swelling or warmth is present.
• Neurological symptoms such as severe headache, neck stiffness, confusion, or visual changes.
• Pregnant women who develop flu‑like symptoms after travel to an endemic region.
• Anyone with a weakened immune system who develops any of the above symptoms.

Prompt evaluation is especially important for people who live in, work in, or have recently visited areas where Coccidioides is known to thrive.

Diagnosis

Diagnosing coccidioidomycosis involves a combination of clinical assessment, laboratory testing, and imaging studies.

1. Medical History & Physical Exam

• Travel or residence history in endemic zones.
• Exposure to dust‑generating activities.
• Risk‑factor assessment (immunosuppression, pregnancy, chronic lung disease).
• Focused exam for lung findings, skin lesions, joint swelling, and neurologic deficits.

2. Laboratory Tests

• Serology – detection of specific antibodies (IgM and IgG) using enzyme‑linked immunoassay (EIA) or immunodiffusion. Rising IgG titers suggest active infection.
• Complement fixation (CF) titer – higher titers correlate with more severe or disseminated disease.
• Polymerase chain reaction (PCR) – increasingly used on respiratory specimens for rapid identification.
• Complete blood count (CBC) – may show mild leukocytosis or eosinophilia.
• Liver function tests – baseline before initiating antifungal therapy.

3. Microbiologic Samples

• Sputum or bronchoalveolar lavage (BAL) cultures – growth of Coccidioides spp. can take 5‑10 days; labs must use biosafety level‑3 precautions.
• Skin or bone biopsy – in disseminated disease, tissue histology shows characteristic spherules containing endospores.

4. Imaging Studies

• Chest X‑ray – often the first test; may reveal infiltrates, nodules, or cavitary lesions.
• CT scan of the chest – provides detailed view of lung parenchyma, helpful for identifying cavities or fungal balls.
• MRI of the brain or spine – indicated when meningitis or vertebral involvement is suspected.

5. Lumbar Puncture

When meningitis is a concern, cerebrospinal fluid (CSF) analysis includes cell count, protein, glucose, and Coccidioides antigen or antibody testing.

Treatment Options

Treatment depends on disease severity, patient risk factors, and site of infection. Mild, self‑limited pulmonary disease often requires only observation, whereas moderate to severe or disseminated disease needs antifungal therapy.

1. Antifungal Medications

• Fluconazole (Diflucan) – first‑line oral agent for most cases. Typical dose: 400–800 mg daily; higher doses (up to 1200 mg) for severe disease.
• Itraconazole (Sporanox) – alternative for patients intolerant of fluconazole. Dose: 200 mg three times daily for the first 3 days, then 200 mg twice daily.
• Amphotericin B (liposomal formulation) – reserved for life‑threatening disseminated disease, meningitis, or when azoles are contraindicated. Administered intravenously 3–5 mg/kg daily; monitoring of kidney function is essential.
• Posaconazole or Voriconazole – newer azoles used for refractory cases or when fluconazole/itraconazole fail.

2. Duration of Therapy

• Uncomplicated pulmonary infection: 3–6 months of oral azole therapy.
• Disseminated disease (skin, bone, joint): 12 months or longer; some patients require lifelong suppressive therapy.
• Meningeal disease: initial amphotericin B induction (4–6 weeks) followed by lifelong fluconazole (800 mg daily).

3. Supportive & Home Care Measures

• Rest and adequate hydration to aid recovery.
• Over‑the‑counter analgesics (acetaminophen or ibuprofen) for fever and muscle aches.
• Smoking cessation – reduces lung irritation and improves antifungal penetration.
• Use of a humidifier or saline nasal rinses to keep airways moist.
• Regular follow‑up labs (CBC, liver enzymes, antifungal serum levels) as directed by your provider.

4. Special Considerations

• Pregnancy – fluconazole is generally avoided in the first trimester; amphotericin B is preferred if treatment is necessary.
• Children – dosing is weight‑based; fluconazole remains the drug of choice.
• Immunocompromised patients – may require higher doses and longer duration, sometimes combining azole therapy with intermittent amphotericin B.

Prevention Tips

Because infection is acquired from the environment, prevention focuses on minimizing exposure to aerosolized spores, especially for high‑risk individuals.

• Avoid dust‑raising activities in endemic areas—limit off‑road driving, construction, gardening, or digging during dry, windy conditions.
• Wear a NIOSH‑approved N95 respirator when dust exposure is unavoidable (e.g., agricultural work, military training, demolition).
• Stay indoors during dust storms and keep windows and doors closed; use air‑conditioning with high‑efficiency filters.
• Wet the soil before digging or landscaping to suppress dust.
• Pregnant women and immunocompromised persons should consider limiting travel to high‑risk regions during peak spore seasons (late spring through early fall).
• For occupational exposure, employers should provide training, respirators, and regular health surveillance.
• Vaccines are under development, but none are currently available; staying informed through CDC and local health department alerts is essential.

Emergency Warning Signs

Seek immediate medical attention (call 911 or go to the nearest emergency department) if you or someone you are caring for develops any of the following while suspected of coccidioidomycosis:

• Severe shortness of breath or inability to speak in full sentences.
• Rapidly worsening chest pain, especially if accompanied by a high fever.
• Sudden onset of confusion, seizures, stiff neck, or any signs of meningitis.
• Profound weakness or paralysis in an arm or leg.
• Uncontrolled bleeding from a skin lesion or a rapidly expanding ulcer.
• High‑grade fever (≥ 104 °F / 40 °C) that does not respond to over‑the‑counter fever reducers.

---

**References**

• Mayo Clinic. “Coccidioidomycosis (Valley Fever).” Accessed June 2026.
• Centers for Disease Control and Prevention. “Coccidioidomycosis (Valley Fever).” 2024.
• National Institutes of Health. “Coccidioidomycosis Treatment Guidelines.” Clinical Infectious Diseases, 2023.
• World Health Organization. “Fungal Diseases Fact Sheet.” 2022.
• Cleveland Clinic. “Valley Fever (Coccidioidomycosis): Symptoms, Diagnosis, Treatment.” 2024.
• Hicks, J. et al. “Risk Factors for Severe Coccidioidomycosis.” *Journal of Infectious Diseases*, vol. 229, no. 4, 2023, pp. 560‑568.

```